Stifel analyst Nathan Jones upgraded Xylem (XYL) to Buy from Hold with a price target of $124, up from $115, after the company entered into a definitive agreement to acquire Evoqua (AQUA) in an all-stock transaction. The "low fundamental risk acquisition" provides "strong opportunity to drive higher growth together than separate," the analyst tells investors in a research note. The firm says Xylem shares are "on sale" following yesterday’s selloff and that the deal "is compelling just considering the cost synergies."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on XYL:
- Xylem stock reaction to Evoqua deal ‘confounding,’ says Stifel
- Xylem’s buyout of Evoqua ‘pricey,’ with no accretion, says Raymond James
- Xylem falls -9.9%
- Xylem falls -8.7%
- Xylem Tanks on $7.5B Evoqua Acquisition
Questions or Comments about the article? Write to editor@tipranks.com